The University at Buffalo (UB) School of Pharmacy and Pharmaceutical Sciences is enrolling adults currently admitted to the Buffalo General Medical Center and being treated by the cardiology team for a 3-month study. The goal of the study is to see if better communication between a hospital pharmacist and a patient’s primary care physician is helpful after being released from the hospital. Read More

Adults 18 years or older Admitted to Buffalo General Medical Center and are being treated by the cardiology team

The University at Buffalo (UB) Department of Medicine is enrolling adults with atrial fibrillation (or “AFib”) that are worried about their risk of having a stroke. People with AFib have a heart condition that causes the upper chambers of their hearts to beat irregularly, or differently than they should. The goal of the study is to see if a new study device (the CLAAS System) can reduce the risk of stroke without the need for blood thinners. Read More

Adults 18 years or older Have been diagnosed with atrial fibrillation (or AFib) Are at risk for stroke

The University at Buffalo (UB) Department of Medicine is enrolling adults with complex heart disease in a clinical trial. The goal of the study is to see if a new heart pump (the Impella ECP) can help the heart during surgery. Read More

Adults 18 years or older Have complex heart disease Need to have heart surgery to help treat their heart disease

The University at Buffalo (UB) Department of Surgery is looking for adults that have been diagnosed with peripheral arterial disease (or when plaque builds up on artery walls and makes it more difficult for blood to flow) for a study. The goal of the study is to see if there are differences between two devices (the VBX Device and the Bare Metal Stent) in helping to treat peripheral arterial disease. Read More

Adults over the age of 18 years old Have peripheral arterial disease Are scheduled for iliac artery surgery

This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period. Read More

1) History of chronic stable, NYHA class II to IV CHF 2) NT-proBNP 600 - 6000 3) LVEF of <40% assessed within 12 months before randomization

Study to assess the effect of dapagliflozin as compared with placebo in patients with heart failure who have been stabilized during hospitalization for acute heart failure. Patients will be followed for a maximum of 2 months. Read More

1. Currently hospitalized with AHF with symptoms of AHF.
2. LVEF <40% within the past 12 months
3. Elevated NT-proBNP, >1600 pg/ml
4. > 18 years of age
5. eGFR >30

-Adults ages 18-80
-Has a single unruptured target intracranial aneurysm (IA) located on the internal carotid artery (ICA) or its branches.

This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR). The purpose of this study is to look at the safety and effectiveness of this new investigational device compared to the standard medical treatment. Read More

Adults ages 18+
Diagnosed with Tricuspid Regurgitation/Insufficiency

This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More

Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).

This study enrolls people who have mitral regurgitation (MR). Mitral regurgitation happens when the heart’s mitral valve does not close tightly. The purpose of this trial is to evaluate a new investigational device called the Tendyne™ Mitral Valve System. The Tendyne Mitral Valve System is designed for the treatment of a diseased, damaged or malfunctioning mitral valve. This trial will collect information on how safe and effective this device is to treat a leaking mitral valve compared to the commercially available MitraClip® System. Read More

-Adults ages 18+.
-Have symptomatic, moderate-to-severe/severe mitral regurgitation (MR) or severe mitral annular calcification (MAC)
-Your medical providers have decided a transcatheter therapy is more appropriate than open surgery.